JPWO2020188333A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188333A5 JPWO2020188333A5 JP2021555402A JP2021555402A JPWO2020188333A5 JP WO2020188333 A5 JPWO2020188333 A5 JP WO2020188333A5 JP 2021555402 A JP2021555402 A JP 2021555402A JP 2021555402 A JP2021555402 A JP 2021555402A JP WO2020188333 A5 JPWO2020188333 A5 JP WO2020188333A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- input settings
- configuration
- administering
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 11
- 239000008177 pharmaceutical agent Substances 0.000 claims description 9
- 230000001364 causal effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102100013052 CENPJ Human genes 0.000 claims description 7
- 101700011445 CENPJ Proteins 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010002091 Anaesthesia Diseases 0.000 claims description 4
- 230000037005 anaesthesia Effects 0.000 claims description 4
- 229940079593 drugs Drugs 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Description
主題の特定の実施形態が説明されてきた。他の実施形態は、以下の特許請求の範囲内とする。例えば、特許請求の範囲に記載されているアクションは、異なる順序で実行することができ、それでも望ましい結果を達成することができる。一例として、添付の図に示されているプロセスは、望ましい結果を実現するために、示された特定の順序又は連続順序を必ずしも必要としない。場合によっては、マルチタスク及び並列処理が有利な場合がある。
なお、以上の各実施形態に加えて以下の態様について付記する。
(付記1)
患者に治療を提供する入力設定の構成を、入力設定と前記患者に対する治療の効果との間の現在の因果関係を測定する因果モデルに基づいて選択することと、
前記患者に対する前記治療の効果の測定値を受け取ることと、
前記患者に対する前記治療の前記効果の前記測定値に基づいて、前記因果モデルを調整することと、を繰り返し実行することを含む、方法。
(付記2)
前記入力設定の構成を選択することが、内部制御パラメータのセットに基づいて前記入力設定の構成を選択することを含み、
前記方法は、前記患者に対する前記治療の前記効果の前記測定値に基づいて前記内部制御パラメータを調整することを更に含む、付記1に記載の方法。
(付記3)
前記患者に対する前記治療の前記効果の前記測定値が、
前記患者の血圧レベル、
前記患者の心拍数、
前記患者の深部体温、
前記患者の生理学的シグナルに関連する1つ以上の測定値、
前記患者の睡眠の質に関連する1つ以上の測定値、又は、
血液成分に関連する1つ以上の測定値、
のうちの1つ以上を含む、付記1又は2に記載の方法。
(付記4)
前記患者の生理学的シグナルに関連する前記測定値が、
前記患者の痛みのレベル、又は、
前記患者の欲求に対する抵抗の測定値、
のうちの1つ以上を含む、付記3に記載の方法。
(付記5)
前記患者の睡眠の前記質に関連する前記測定値が、睡眠中の前記患者の呼吸障害エピソードの数を含む、付記3又は4に記載の方法。
(付記6)
血液成分に関する前記測定値が、
前記患者のコレステロール値、
前記患者の血糖値、
患者のA1Cレベル、
前記患者の血中トロポニンレベル、
所与の疾患のバイオマーカー、又は、
前記患者中の物質のPK曲線、
のうちの1つ以上を含む、付記3~5のいずれか一項に記載の方法。
(付記7)
前記入力設定が、
前記患者への1つ以上の医薬品の投与に関連する1つ以上の入力設定、
前記患者の食物摂取に関連する1つ以上の入力設定、
CPAPマシンの1つ以上の入力設定、
前記患者への麻酔の管理に関連する1つ以上の入力設定、又は、
前記治療の周囲環境に関連する1つ以上の入力設定、
のうちの1つ以上を含む、付記1~6のいずれか一項に記載の方法。
(付記8)
前記患者への1つ以上の医薬品の投与に関連する前記入力設定が、
投与される所与の医薬品の選択されたタイプ、
投与される2つ以上の医薬品の選択された組み合わせ、
所与の医薬品若しくはプラセボのいずれかを投与すること、
所与の医薬品の投与スケジュール、
1用量あたりの投与される所与の医薬品の量、又は、
所与の医薬品が投与される前記患者の場所、
のうちの1つ以上を含む、付記7に記載の方法。
(付記9)
前記患者への医薬品の投与に関連する前記入力設定が、前記医薬品を投与する装置の構成を定義する1つ以上の設定を含む、付記7又は8に記載の方法。
(付記10)
前記医薬品を投与する装置の構成を定義する前記1つ以上の設定が、マイクロニードルパッチの構成を定義する1つ以上の設定を含む、付記9に記載の方法。
(付記11)
マイクロニードルパッチの構成を定義する前記設定が、
パッチサイズ、
前記パッチのアスペクト比、
前記パッチ上の前記マイクロニードルの形状、
前記パッチ上のマイクロニードルの数、
前記パッチ上のマイクロニードルの密度、又は、
前記パッチ上のマイクロニードルのサイズ、
のうちの1つ以上を含む、付記10に記載の方法。
(付記12)
前記患者の食物摂取に関連する前記入力設定が、
前記治療中に前記患者が摂取する食物カロリー数、
前記治療中に前記患者が摂取する食物カロリーのタイプ、又は、
前記患者が食べる時間帯、
のうちの1つ以上を含む、付記7~11のいずれか一項に記載の方法。
(付記13)
CPAPマシンの前記入力設定が、
前記CPAPマシンの空気圧、
前記CPAPマシンの空気量、
前記CPAPマシンのデューティサイクル、又は、
前記CPAPマシンと組み合わせた毛布若しくはウォーマーの使用、
のうちの1つ以上を含む、付記7~12のいずれか一項に記載の方法。
(付記14)
前記患者への麻酔の管理に関連する前記入力設定が、
切開前の麻酔導入時間、又は、
毛布若しくはウォーマーの使用、
のうちの1つ以上を含む、付記7~13のいずれか一項に記載の方法。
(付記15)
前記治療の周囲環境に関連する前記入力設定が、
治療中の温度、又は、
治療中の空気の流れ、
のうちの1つ以上を含む、付記7~14のいずれか一項に記載の方法。
(付記16)
前記構成を選択することが、考慮に入れられる外部変数の所定のセットのそれぞれの測定値に基づいて、前記構成を選択することを含み、
前記方法は、外部変数の前記所定のセットの影響をパラメータ化する内部制御パラメータを調整することを更に含む、付記1~15のいずれか一項に記載の方法。
(付記17)
外部変数の前記所定のセットが、
前記患者の1つ以上の個人的特性、又は、
前記治療の周囲環境に関連する1つ以上の外部変数、
のうちの1つ以上を含む、付記16に記載の方法。
(付記18)
前記個人的特性が、
前記患者の体重、
前記患者の年齢、
前記患者の性別、
前記患者の平均カロリー摂取量、
前記患者の1つ以上の遺伝子マーカー、
前記患者の活動レベル、
前記患者の睡眠レベル、
前記患者のボディマスインデックス、
前記患者の発汗レベル、又は、
前記患者が使用するスキンローションの量、
のうちの1つ以上を含む、付記17に記載の方法。
(付記19)
前記治療の周囲環境に関連する前記外部変数が、治療中の周囲温度を含む、付記17又は18に記載の方法。
(付記20)
患者に治療を提供する入力設定の構成を取得することと、
前記患者に対する前記治療の効果の測定値を判定することと、
入力設定と前記患者への効果との間の現在の因果関係を測定する因果モデルを維持するシステムに、前記患者への前記治療の前記効果の前記測定値を提供することと、を繰り返し実行することを含む、方法。
(付記21)
1つ以上のコンピュータと、前記1つ以上のコンピュータによって実行された場合に前記1つ以上のコンピュータに付記1~20のいずれか一項に記載のそれぞれの方法の動作を実行させる命令を記憶する1つ以上の記憶デバイスと、を含む、システム。
(付記22)
1つ以上のコンピュータによって実行された場合に前記1つ以上のコンピュータに付記1~20のいずれか一項に記載のそれぞれの方法の動作を実行させる命令を記憶する、1つ以上のコンピュータ可読記憶媒体。
Particular embodiments of the subject matter have been described. Other embodiments are within the scope of the following claims. For example, the actions recited in the claims can be performed in a different order and still achieve desirable results. As an example, the processes depicted in the accompanying figures do not necessarily require the particular order shown or sequential order to achieve desirable results. In some cases, multitasking and parallel processing may be advantageous.
In addition to the above embodiments, the following aspects will be added.
(Appendix 1)
selecting a configuration of input settings for providing therapy to a patient based on a causal model that measures current causal relationships between input settings and effects of therapy on the patient;
receiving a measure of the effect of the treatment on the patient;
adjusting the causal model based on the measurement of the effect of the treatment on the patient; and repeatedly performing.
(Appendix 2)
selecting the configuration of input settings comprises selecting the configuration of input settings based on a set of internal control parameters;
2. The method of Claim 1, wherein said method further comprises adjusting said internal control parameter based on said measurement of said effect of said treatment on said patient.
(Appendix 3)
wherein said measure of said effect of said treatment on said patient is
the patient's blood pressure level;
heart rate of the patient;
core body temperature of said patient;
one or more measurements related to the patient's physiological signals;
one or more measurements related to the patient's sleep quality; or
one or more measurements related to blood components;
3. The method of clause 1 or 2, comprising one or more of
(Appendix 4)
wherein said measurements related to physiological signals of said patient are
the patient's level of pain; or
a measure of the patient's resistance to cravings;
3. The method of clause 3, comprising one or more of
(Appendix 5)
5. The method of Clause 3 or 4, wherein the measure related to the quality of sleep of the patient comprises the number of disordered breathing episodes of the patient during sleep.
(Appendix 6)
wherein said measurement of a blood component is
the patient's cholesterol level;
the patient's blood glucose level;
patient's A1C level,
the blood troponin level of said patient;
a biomarker for a given disease, or
a PK curve for a substance in said patient;
6. The method of any one of clauses 3-5, comprising one or more of
(Appendix 7)
The input settings are
one or more input settings associated with administration of one or more pharmaceutical agents to the patient;
one or more input settings related to the patient's food intake;
one or more input settings of the CPAP machine;
one or more input settings related to administering anesthesia to the patient; or
one or more input settings related to the treatment environment;
7. The method of any one of clauses 1-6, comprising one or more of
(Appendix 8)
wherein the input settings associated with administration of one or more pharmaceutical agents to the patient comprise:
the selected type of a given medicinal product to be administered;
a selected combination of two or more pharmaceutical agents to be administered;
administering either a given drug or a placebo;
dosing schedule for a given medicinal product,
the amount of a given drug administered per dose, or
the location of said patient where a given pharmaceutical agent is administered;
8. The method of clause 7, comprising one or more of
(Appendix 9)
9. The method of clause 7 or 8, wherein said input settings related to administering a medication to said patient comprise one or more settings defining a configuration of a device for administering said medication.
(Appendix 10)
10. The method of clause 9, wherein the one or more settings defining the configuration of the device for administering the pharmaceutical agent comprise one or more settings defining the configuration of a microneedle patch.
(Appendix 11)
said settings defining the configuration of the microneedle patch,
patch size,
an aspect ratio of said patch;
the shape of the microneedles on the patch;
the number of microneedles on said patch;
density of microneedles on the patch, or
the size of the microneedles on said patch;
11. The method of clause 10, comprising one or more of
(Appendix 12)
wherein the input setting related to the patient's food intake comprises:
number of food calories consumed by said patient during said treatment;
type of food calories ingested by said patient during said treatment; or
a time period during which the patient eats;
12. The method of any one of clauses 7-11, comprising one or more of
(Appendix 13)
The input settings of the CPAP machine are:
air pressure of said CPAP machine;
the amount of air in the CPAP machine;
the duty cycle of the CPAP machine; or
use of a blanket or warmer in combination with the CPAP machine;
13. The method of any one of clauses 7-12, comprising one or more of
(Appendix 14)
said input settings related to administration of anesthesia to said patient comprising:
anesthesia induction time before incision, or
use of blankets or warmers,
14. The method of any one of clauses 7-13, comprising one or more of
(Appendix 15)
wherein the input settings related to the treatment environment include:
temperature during treatment, or
air flow during treatment,
15. The method of any one of clauses 7-14, comprising one or more of
(Appendix 16)
selecting said configuration comprises selecting said configuration based on respective measurements of a predetermined set of external variables taken into account;
16. The method of any one of clauses 1-15, wherein the method further comprises adjusting an internal control parameter that parameterizes the influence of the predetermined set of external variables.
(Appendix 17)
the predetermined set of external variables is
one or more personal characteristics of the patient; or
one or more external variables related to the treatment environment;
17. The method of clause 16, comprising one or more of
(Appendix 18)
said personal characteristics are
weight of the patient;
age of said patient;
sex of said patient;
the patient's average caloric intake;
one or more genetic markers of said patient;
activity level of the patient;
sleep level of the patient;
a body mass index of said patient;
the patient's sweat level; or
amount of skin lotion used by said patient;
18. The method of clause 17, comprising one or more of
(Appendix 19)
19. The method of clause 17 or 18, wherein the external variable related to the ambient environment of the treatment includes ambient temperature during treatment.
(Appendix 20)
obtaining a configuration of input settings for providing therapy to a patient;
determining a measure of the effect of the treatment on the patient;
providing said measurements of said effects of said treatment on said patient to a system that maintains a causal model measuring current causal relationships between input settings and effects on said patient. method, including
(Appendix 21)
storing one or more computers and instructions which, when executed by said one or more computers, cause said one or more computers to perform the operations of each of the methods of any one of Appendixes 1-20 A system, including one or more storage devices.
(Appendix 22)
One or more computer readable memories storing instructions which, when executed by one or more computers, cause said one or more computers to perform the operations of the respective method of any one of Clauses 1-20. medium.
Claims (5)
前記患者に対する前記治療の効果の測定値を受け取ることと、
前記患者に対する前記治療の前記効果の前記測定値に基づいて、前記因果モデルを調整することと、を繰り返し実行することを含む、方法。 selecting a configuration of input settings for providing therapy to a patient based on a causal model that measures current causal relationships between input settings and effects of therapy on the patient;
receiving a measure of the effect of the treatment on the patient;
adjusting the causal model based on the measurement of the effect of the treatment on the patient; and repeatedly performing .
前記患者への1つ以上の医薬品の投与に関連する1つ以上の入力設定、
前記患者の食物摂取に関連する1つ以上の入力設定、
CPAPマシンの1つ以上の入力設定、
前記患者への麻酔の管理に関連する1つ以上の入力設定、又は、
前記治療の周囲環境に関連する1つ以上の入力設定、
のうちの1つ以上を含む、請求項1に記載の方法。 The input settings are
one or more input settings associated with administration of one or more pharmaceutical agents to the patient;
one or more input settings related to the patient's food intake;
one or more input settings of the CPAP machine;
one or more input settings related to administering anesthesia to the patient; or
one or more input settings related to the treatment environment;
2. The method of claim 1 , comprising one or more of:
投与される所与の医薬品の選択されたタイプ、
投与される2つ以上の医薬品の選択された組み合わせ、
所与の医薬品若しくはプラセボのいずれかを投与すること、
所与の医薬品の投与スケジュール、
1用量あたりの投与される所与の医薬品の量、又は、
所与の医薬品が投与される前記患者の場所、
のうちの1つ以上を含む、請求項2に記載の方法。 wherein the input settings associated with administration of one or more pharmaceutical agents to the patient comprise:
the selected type of a given medicinal product to be administered;
a selected combination of two or more pharmaceutical agents to be administered;
administering either a given drug or a placebo;
dosing schedule for a given medicinal product,
the amount of a given drug administered per dose, or
the location of said patient where a given pharmaceutical agent is administered;
3. The method of claim 2 , comprising one or more of:
前記方法は、外部変数の前記所定のセットの影響をパラメータ化する内部制御パラメータを調整することを更に含む、請求項1に記載の方法。 selecting said configuration comprises selecting said configuration based on respective measurements of a predetermined set of external variables taken into account;
2. The method of claim 1, wherein the method further comprises adjusting internal control parameters that parameterize the effects of the predetermined set of external variables .
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962818816P | 2019-03-15 | 2019-03-15 | |
US62/818,816 | 2019-03-15 | ||
US201962898797P | 2019-09-11 | 2019-09-11 | |
US62/898,797 | 2019-09-11 | ||
PCT/IB2019/058423 WO2020188333A1 (en) | 2019-03-15 | 2019-10-03 | Individualized medicine using causal models |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022524869A JP2022524869A (en) | 2022-05-10 |
JPWO2020188333A5 true JPWO2020188333A5 (en) | 2022-10-14 |
Family
ID=72519218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021555402A Pending JP2022524869A (en) | 2019-03-15 | 2019-10-03 | Individualized medical care using a causal model |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220189632A1 (en) |
EP (1) | EP3938979A4 (en) |
JP (1) | JP2022524869A (en) |
CN (1) | CN114072827A (en) |
WO (1) | WO2020188333A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020188328A1 (en) | 2019-03-15 | 2020-09-24 | 3M Innovative Properties Company | Method of performing a process and optimizing control signals used in the process |
US11837106B2 (en) * | 2020-07-20 | 2023-12-05 | Koninklijke Philips N.V. | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7860583B2 (en) * | 2004-08-25 | 2010-12-28 | Carefusion 303, Inc. | System and method for dynamically adjusting patient therapy |
EP1418976B1 (en) * | 2001-07-31 | 2013-06-26 | Scott Laboratories, Inc. | Apparatuses and methods for titrating drug delivery |
US20050096637A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Sensing food intake |
DE602006005333D1 (en) * | 2006-03-06 | 2009-04-09 | Gen Electric | Automatic calibration of a person's sensitivity to a drug |
US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
CN102014998B (en) * | 2008-03-05 | 2014-06-18 | 雷斯梅德有限公司 | Blood glucose regulation through control of breathing |
US10305503B2 (en) * | 2013-03-07 | 2019-05-28 | Texas Instruments Incorporated | Analog to digital conversion with pulse train data communication |
US20150006192A1 (en) | 2013-06-26 | 2015-01-01 | WellDoc, Inc. | Systems and methods for clinical decision-making |
US20170277841A1 (en) * | 2016-03-23 | 2017-09-28 | HealthPals, Inc. | Self-learning clinical intelligence system based on biological information and medical data metrics |
US11191881B2 (en) * | 2017-12-13 | 2021-12-07 | Fresenius Medical Care Holdings, Inc. | Articles for warming and monitoring patient during dialysis treatment |
WO2019209845A1 (en) * | 2018-04-23 | 2019-10-31 | Mould Diane R | Systems and methods for modifying adaptive dosing regimens |
WO2021016465A1 (en) * | 2019-07-23 | 2021-01-28 | The Regents Of The University Of California | Minimally invasive continuous analyte monitoring for closed-loop treatment applications |
-
2019
- 2019-10-03 JP JP2021555402A patent/JP2022524869A/en active Pending
- 2019-10-03 EP EP19920468.6A patent/EP3938979A4/en active Pending
- 2019-10-03 CN CN201980094083.6A patent/CN114072827A/en active Pending
- 2019-10-03 US US17/436,743 patent/US20220189632A1/en active Pending
- 2019-10-03 WO PCT/IB2019/058423 patent/WO2020188333A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Field et al. | Massage therapy by parents improves early growth and development | |
Kaplan et al. | Airway pressure release ventilation increases cardiac performance in patients with acute lung injury/adult respiratory distress syndrome | |
Ngan Kee et al. | Randomized comparison of closed-loop feedback computer-controlled with manual-controlled infusion of phenylephrine for maintaining arterial pressure during spinal anaesthesia for caesarean delivery | |
Gozalo-Marcilla et al. | Comparison of the influence of two different constant-rate infusions (dexmedetomidine versus morphine) on anaesthetic requirements, cardiopulmonary function and recovery quality in isoflurane anaesthetized horses | |
Akça et al. | Effect of intra‐operative end‐tidal carbon dioxide partial pressure on tissue oxygenation | |
Sanuki et al. | Effect of nasal high-flow oxygen therapy on the swallowing reflex: an in vivo volunteer study | |
Burgert et al. | The effects of proximal and distal routes of intraosseous epinephrine administration on short-term resuscitative outcome measures in an adult swine model of ventricular fibrillation: a randomized controlled study | |
Nannarone et al. | Clinical comparison of two regimens of lidocaine infusion in horses undergoing laparotomy for colic | |
JPWO2020188333A5 (en) | ||
Hering et al. | Maternal haemodynamics and lung water content during percutaneous fetoscopic interventions under general anaesthesia | |
Holowaychuk et al. | Care of the patient with intracranial disease | |
WO2017055488A1 (en) | Volume adjustment infusion system and method | |
US20180280620A1 (en) | Shivering adjustment infusion system and method | |
Paranjape et al. | Use of a modified passive leg-raising maneuver to predict fluid responsiveness during experimental induction and correction of hypovolemia in healthy isoflurane-anesthetized pigs | |
Xue et al. | Respiratory system responsiveness in rabbits in vivo is reduced by prolonged continuous positive airway pressure | |
Abeles et al. | The use of conscious sedation for outpatient dermatologic surgical procedures | |
Schäffer et al. | Cardiorespiratory effects of epidural anesthesia using lidocaine with morphine or dexmedetomidine in capuchin monkeys (Sapajus sp.) undergoing bilateral tubal ligation surgery, anesthetized with isoflurane | |
Powers | Common procedures in psittacines | |
Jack et al. | Cardiovascular changes after achieving constant effect site concentration of propofol | |
Pourzand et al. | Hemodynamics, survival and neurological function with early versus delayed automated head-up CPR in a porcine model of prolonged cardiac arrest | |
Wong et al. | Diabetes type 1 and type 2—Insulin delivery systems | |
Dix et al. | Methods used in veterinary practice to maintain the temperature of intravenous fluids | |
JP2021506933A (en) | Treatment of Exercise-Induced Hypoglycemia in Type 1 Diabetes and Insulin Use Type 2 Diabetes | |
US20180280615A1 (en) | Electrolyte adjustment infusion system and method | |
Smart | Counting fat and protein: a dietitian’s perspective |